Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial-Reference-Cited by-同舟云学术

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

Published:2023-11 Issue:10416 Volume:402 Page:2004-2017
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Heerspink Hiddo J L,Kiyosue Arihiro,Wheeler David C,Lin Min,Wijkmark Emma,Carlson Glenn,Mercier Anne-Kristina,Åstrand Magnus,Ueckert Sebastian,Greasley Peter J,Ambery Phil

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease;Kohan;Br J Clin Pharmacol,2013

2. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases;Jager;Nephrol Dial Transplant,2019

3. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017;Bikbov;Lancet,2020

4. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention;Gansevoort;Lancet,2013

5. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials;Baigent;Lancet,2022

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelin Receptor Antagonists Plus Sodium-Glucose Cotransporter 2 Inhibitors;Journal of the American Society of Nephrology;2024-09-04

2. Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives;Transplantation;2024-08-29

3. The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial;British Journal of Pharmacology;2024-08-19

4. Therapy of IgA nephropathy: time for a paradigm change;Frontiers in Medicine;2024-08-15

5. Contemporary review of IgA nephropathy;Frontiers in Immunology;2024-08-12